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Abstract
Diabetic retinopathy (DR) is a complication of diabetes due to damage of blood vessels in the retina. Aside from being a major cause of blindness
in the world, DR also has a significant impact on quality of life. Although there are methods to delay the progression of DR, there are no existing
therapeutic regimens for early intervention. Thus, it is critical to develop cost-effective therapies towards preventing DR development.
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Opinion
The worldwide prevalence of diabetes is reported as 463 million
(substantially exceeding the US population) and it is projected to
rise to 700 million by 2045 [1]. Specifically, in the United States, 1 in
5 diabetics remain undiagnosed, which can only increase the current
estimate on number of cases and also the scope to its management
[2]. It has been well established that a longstanding history of
uncontrolled diabetes can lead to multi-organ dysfunction, such as
nephropathy, peripheral vascular disease, and diabetic retinopathy
(DR).

DR is a microvascular complication and a major cause of

blindness in the world. The rapid formation of new blood vessels
in the retina will lead to induce microaneurysms and a loss of
vasculature integrity. DR not only affects the eye, but also has a
detrimental impact on a person’s quality of life. A cross-sectional,
population-based study assessed the health-related quality of life
and the impact of DR in 1,064 participants. The visual impairment
related to DR was found to have a profound effect on social
factors, such as mobility, independence, and mental health [3].
This study suggests that people with diabetes, who receive proper
management of their disease, are living healthier and happier lives.
When it comes to preventing diabetes-related complications,
patients are generally advised to have good control over one’s blood
sugar levels and blood pressure from an early standpoint. Making

lifestyle modifications can delay the onset of DR, however, since this
complication is initially asymptomatic, it’s difficult to make an early
prognosis. It is not until the later stages of DR that symptoms begin
to manifest with various visual disturbances. Current treatments
are focused to preserve vision with the use of vascular endothelial
growth factor inhibitors to attenuate growth of new blood vessels
or laser photocoagulation to seal leaking blood vessels in the retina.

However, these treatments often impose a financial burden on
patients, given the need for frequent administration. This suggests
a need for cost-effective therapeutic approaches aimed toward
preventing DR, while encouraging continuity of care. A novel
molecular pathway on the pathogenesis of DR may serve to identify
potential therapeutic targets for early intervention.
One of the hallmarks of early DR is the loss of human retinal
pericytes (HRP) through apoptosis. However, the exact mechanisms
that promote pericyte dropout are unknown. Pericytes are
contractile cells that envelop the endothelial cells of capillaries.
They help maintain adequate blood flow, as well as the integrity
of the blood-brain barrier [4,5]. There are several proposed
signaling pathways on the pathogenesis of DR. One of them involve
the inflammatory response to diabetes in which HRP apoptosis is
caused by TGFβ secreted by macrophages of the immune system
when they enter the retina. TGFβ results in an increase of TGFβ-
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induced Gene Human Clone 3 (BIGH3) that binds to integrin
receptors in HRP, leading to apoptosis [6].

BIGH3 is an extracellular pro-apoptotic protein that
accumulates in the retinal vessels. BIGH3 mediates cellular
adhesion, proliferation, and apoptosis through an autocrine
signalling mechanism by interacting with HRP integrin receptors
[7,8]. Previous studies have demonstrated that treatment of
increased concentrations of TGFβ causes a rise in BIGH3 synthesis
in mammalian pericytes and endothelial cells, followed by
apoptosis [9,10]. This suggests BIGH3-mediated apoptosis in HRP
may contribute to the progression of DR.
Although there is supporting evidence of an association
between BIGH3 and DR, the complete molecular pathway of
BIGH3-mediated apoptosis in HRP warrants further investigation.
As HRP are vital to maintaining retinal vasculature, it is critical to
find an innovative molecular pathway and therapy targets to inhibit
the BIGH3-bound integrin. Overall, a molecular therapy from this
pathway may not only prevent DR, but also improve the patients’
quality of life.
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